Combined chemo-radiotherapy for Stage II-III non-small cell lung cancer
- VernacularTitle:综合治疗Ⅱ+Ⅲ期非小细胞肺癌疗效分析
- Author:
Yangjun YUE
;
Yunsheng LI
;
Sha LI
;
Shihua WEI
;
Zhongze TIAN
- Publication Type:Journal Article
- Keywords:
Lung neoplasms/radiotherapy;
Lung neoplasms /chemotherapy;
Combined modality therapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
1993;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of induction chemotherapy plus radiotherapy (ICRT) and concurrent chemotherapy plus radiotherapy (CCRT) for Stage Ⅱ -Ⅲ non-small cell lung carcinoma (NSCLC) . Methods From July 19% to July 1999, 64 patients with Stage Ⅱ -Ⅲ NSCLC were randomized into two groups: ICRT group (32 patients) induction chemotherapy with DDP( 100mg/m2,dl) and VP-16 (100mg/m2,dl-d3) per week, one cycle per 4 weeks was given. Radiation was given after 2-3 cycles. CCRT group (32 patients) received radiotherapy plus concurrent chemotherapy with DDP(20 mg/m2,dl-d5) and VP-16 (50 mg/m2,dl-d5) per week for 8 weeks. In either group, radiation was given with a total dose of 60-70 Gy/6-7 weeks. Results One patient was excluded from ICRT group for development of distant metastasis, and 3 from CCRT group for their acute complications or other diseases. The overall response rates ( CR + PR) of ICRT and CCRT groups were 81.3% and 84.4%, respectively . NR + PD rates of both groups were 18.7% and 15.6% . The median survival periods were 13.4 months in ICRT group and 21.6 months in CCRT group (t = 2.58, P
